mardi 29 avril 2014

Risk-assessment approach recommended for biomarker-driven cancer clinical trials

A practical, risk-management approach has been outlined by experts for effective integration of biomarkers into cancer clinical trials. This work provides the international community with a set of common principles by which biomarkers can be integrated into clinical trials, exchange of data can be facilitated, quality promoted, and research accelerated while simultaneously respecting local approaches and legislation. Risk-assessment approach recommended for biomarker-driven cancer clinical trials

Aucun commentaire:

Enregistrer un commentaire